GemcitabineRecent, repeatedEvidence- NCT07900789 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection” · registered Oct 2026
- NCT07777211 · Beijing Gene Key Life Technology Co., Ltd · Phase 2 · live · background · “Nab-paclitaxel and Gemcitabine” · registered Aug 2026
- NCT07701486 · Theriva Biologics SL · Phase 2 · live · background · “Nab-paclitaxel + Gemcitabine” · registered Jul 2026
- NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Gemcitabine (GEM)” · registered May 2026
- NCT07578337 · Nelum Corp · Phase 2 · live · background · “Gemcitabine (1000 mg/m2)” · registered May 2026
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 2433 studies | 2937 studies | background 82 · comparator 21 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07777211 · Beijing Gene Key Life Technology Co., Ltd · Phase 2 · live · background · “Nab-paclitaxel and Gemcitabine” · registered Aug 2026
- NCT07701486 · Theriva Biologics SL · Phase 2 · live · background · “Nab-paclitaxel + Gemcitabine” · registered Jul 2026
- NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Nab-paclitaxel” · registered May 2026
- NCT07578337 · Nelum Corp · Phase 2 · live · background · “Nab-paclitaxel (Abraxane)” · registered May 2026
- NCT07562152 · Immuneering Corporation · Phase 3 · live · comparator · “GnP” · registered Apr 2026
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 1721 studies | 1721 studies | background 39 · comparator 9 |
LeucovorinRecent, repeatedEvidence- NCT07803783 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Leucovorin” · registered Aug 2026
- NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Leucovorin (Calcium Folinate)” · registered May 2026
- NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “Leucovorin” · registered Feb 2026
- NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
- NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “leucovorin” · registered Sep 2024
| Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed | 67 studies | 78 studies | background 14 · comparator 3 |
FluorouracilRecent, repeatedEvidence- NCT07803783 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “5 Fluorouracil” · registered Aug 2026
- NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “5-Fluorouracil” · registered May 2026
- NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “fluorouracil” · registered Feb 2026
- NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
- NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “5-fluorouracil” · registered Sep 2024
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 67 studies | 78 studies | background 14 · comparator 5 |
IrinotecanRecent, repeatedEvidence- NCT07803783 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Liposomal irinotecan” · registered Aug 2026
- NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Irinotecan” · registered May 2026
- NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “Irinotecan” · registered Feb 2026
- NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
- NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “Irinotecan” · registered Sep 2024
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 67 studies | 78 studies | background 6 · comparator 3 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Oxaliplatin” · registered May 2026
- NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “Oxaliplatin” · registered Feb 2026
- NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
- NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “Oxaliplatin” · registered Sep 2024
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Jul 2023
| Sanofi35% of its industry studies | 56 studies | 56 studies | background 14 · comparator 1 |
PaclitaxelRecent, repeatedEvidence- NCT07900789 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection” · registered Oct 2026
- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
- NCT06821503 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Paclitaxel for injection (albumin bound)” · registered Jan 2025
- NCT06752811 · Shanghai Yizhong Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel for Injection (albumin bound )” · registered Dec 2024
- NCT04644068 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Oct 2020
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 44 studies | 77 studies | background 6 · comparator 2 |
Modified FOLFIRINOX RegimenRecent, repeatedEvidence- NCT07522073 · Incyte Corporation · Phase 3 · live · background · “Investigator's choice of chemotherapy” · registered Apr 2026
- NCT07444541 · anova innovation limited · Phase 2 · live · background · “mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]” · registered Feb 2026
- NCT07255404 · BioNTech SE · Phase 2 · live · background · “mFOLFIRINOX” · registered Nov 2025
- NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “mFOLFIRINOX regimen” · registered May 2024
- NCT06069778 · BioNTech SE · Phase 2 · background · “mFOLFIRINOX” · registered Sep 2023
| — | 45 studies | 55 studies | background 8 |
pembrolizumabRecent, repeatedEvidence- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2023
- NCT05070247 · Takeda · Phase 2 · background · “Pembrolizumab” · registered Sep 2021
- NCT04332653 · NeoImmuneTech · Phase 2 · background · “pembrolizumab (KEYTRUDA®)” · registered Mar 2020
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 33 studies | 45 studies | background 8 |
CetuximabRecent, repeatedEvidence- NCT07644559 · Verastem, Inc. · Phase 2 · live · background · “cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)” · registered May 2026
- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
- NCT06973564 · Jacobio Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Cetuximab” · registered Apr 2025
- NCT05039177 · Erasca, Inc. · Phase 2 · background · “Cetuximab” · registered Sep 2021
| Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004) | 34 studies | 35 studies | background 7 |
Antineoplastic AgentsRecent, repeatedEvidence- NCT07689539 · Qingfeng Pharmaceutical Group Co., Ltd. · Phase 3 · live · comparator · “Chemotherapy” · registered Jun 2026
- NCT07262567 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Chemotherapy” · registered Nov 2025
- NCT06962267 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Chemotherapy” · registered Apr 2025
| — | 33 studies | 33 studies | comparator 2 · background 1 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT04956640 · Eli Lilly and Company · Phase 2 · live · background · “Carboplatin” · registered Jul 2021
- NCT04644068 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Oct 2020
- NCT03678883 · Actuate Therapeutics Inc. · Phase 2 · live · background · “Carboplatin.” · registered Sep 2018
| Eli Lilly and Company16% of its industry studies | 22 studies | 66 studies | background 6 |
CisplatinRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Cisplatin” · registered Jul 2023
- NCT04953962 · CanBas Co. Ltd. · Phase 2 · background · “Cisplatin” · registered Jun 2021
- NCT03485209 · Pfizer · Phase 2 · live · background · “cisplatin” · registered Mar 2018
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 22 studies | 33 studies | background 4 |
GNP RegimenRecent, repeatedEvidence- NCT07563738 · Orion Corporation, Orion Pharma · Phase 2 · live · background · “Gemcitabine and nab-paclitaxel” · registered Apr 2026
- NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “Gemcitabine and nab-paclitaxel” · registered Nov 2025
- NCT03417921 · Ability Pharmaceuticals SL · Phase 2 · background · “Gemcitabine and nab-paclitaxel” · registered Jan 2018
| — | 22 studies | 22 studies | background 3 |
PemetrexedRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
| Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized | 22 studies | 22 studies | background 2 |
TemozolomideRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Temozolomide” · registered Mar 2026
- NCT05417594 · AstraZeneca · Phase 2 · live · background · “Temozolomide (TMZ)” · registered May 2022
| Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized | 22 studies | 22 studies | background 2 |